COVID-19 halts the Trauma Market’s Q120 growth, leading to a -2.8% YoY decline globally.
Q120 was tracking as a stable quarter for the US Trauma Market, following Q419’s +3.8% growth, however, this was interrupted in mid-March by the COVID-19 pandemic. The US Trauma Market was down -1.2% YoY for the quarter, with WW revenues declining -2.8%. The non-elective trauma market experienced a reduction in trauma admissions due to the decrease in daily activities and limited driving for most of the US.Among the many topics covered in the comprehensive Q120 Trauma Market Recap* are:
- Complete Trauma Market Highlights
- Slowdown in Urgent Trauma Procedures
- Top Players Derailed by COVID-19 Pandemic in Q120
- Q120 Trauma Regulatory Highlights
As a result of COVID-19 and the stay-at-home orders trauma surgeons reported seeing definite decreases in volumes, with polytrauma being almost negligible in certain cities, according to an OTA COVID-19 Webinar discussion held late March. Geriatric fractures seem to have decreased but to a lesser extent according to the OTA COVID-19 Webinar discussion.
While stay-at-home orders certainly caused a decrease in daily activity that impacted trauma volumes, SmartTRAK believes most trauma fracture fixation procedures presented at facilities were treated. Based on surgeon feedback, only a small portion received conservative treatment if a facility or area was heavily impacted by COVID-19 and ...
*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.